VBI Vaccines Inc  

(Public, NASDAQ:VBIV)   Watch this stock  
Find more results for David Wilde
2.79
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.90 - 5.94
Open     -
Vol / Avg. 0.00/8,182.00
Mkt cap 55.84M
P/E 6.53
Div/yield     -
EPS 0.43
Shares 20.01M
Beta 3.94
Inst. own 42%

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -72.89% -176.82%
Return on average equity -98.40% -
Employees 60 -
CDP Score - -

Address

222 3rd St Ste 2241
CAMBRIDGE, MA 02142-1259
United States - Map
+1-617-8303031 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

VBI Vaccines Inc., formerly Paulson Capital Corp., is a biopharmaceutical company. It is developing technologies that seek to expand vaccine protection in large markets. VBI’s eVLP vaccine platform allows for the design of enveloped (e) virus-like particle (VLP) vaccines that closely mimic the target virus. VBI’s Liquid Particle Vaccines (LPV) technology enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating or elevated temperatures. It is developing a prophylactic vaccine to prevent Cytomegalovirus (CMV) infection. The company’s lead eVLP asset is CMV vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. Its second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. Effective July 25, 2014, Paulson Capital Corp merged with VBI Vaccines.

Officers and directors

Steven H. Gillis Ph.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Jeff R Baxter Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Egidio Nascimento CA Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
David E. Anderson Ph.D. Senior Vice President - Research
Age: 45
Bio & Compensation  - Reuters
T. Adam Buckley Vice President - Operations and Project Management
Age: 39
Bio & Compensation  - Reuters
Marc J. Kirchmeier Ph.D. Vice President - Formulations
Bio & Compensation  - Reuters
Sam Chawla Director
Age: 40
Bio & Compensation  - Reuters
Trent Donald Davis Director
Age: 47
Bio & Compensation  - Reuters
Michael Steinmetz Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Alan P. Timmins Independent Director
Age: 55
Bio & Compensation  - Reuters